A deeper understanding of treatment responses in these tumours will lead to both improvements in their efficacy and a reduction in their side effects and although difficult, targeting GFI1 for tumour therapy may prove to be a promising avenue in the future. This evidence concerns the gene GFI1 and neoplasm.